Margriet Kwint

Real world evidence to audit NTCP-models for acute esophagus toxicity 143 7 Reference 1. Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, et al. Real-World Evidence - What Is It and What Can It Tell Us? N Engl J Med. 2016;375(23):2293-7. 2. Network for Exellence in Health Innovation. Real world evidence: a new era for health care innovation September 2015 [Available from: http://www.nehi.net/writable/publication_ files/file/rwe_issue_brief_final.pdf. 3. Booth CM, Tannock IF. Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence. Br J Cancer. 2014;110(3):551-5. 4. Salathe M, Bengtsson L, Bodnar TJ, Brewer DD, Brownstein JS, Buckee C, et al. Digital epidemiology. PLoS Comput Biol. 2012;8(7):e1002616. 5. Califf RM. Pragmatic clinical trials: Emerging challenges and new roles for statisticians. Clin Trials. 2016;13(5):471-7. 6. Akbarov A, Williams R, Brown B, Mamas M, Peek N, Buchan I, et al. A Two-stage Dynamic Model to Enable Updating of Clinical Risk Prediction from Longitudinal Health Record Data: Illustrated with Kidney Function. Stud Health Technol Inform. 2015;216:696-700. 7. Tamblyn R, Girard N, Dixon WG, Haas J, Bates DW, Sheppard T, et al. Pharmacosurveillance without borders: electronic health records in different countries can be used to address important methodological issues in estimating the risk of adverse events. J Clin Epidemiol. 2016;77:101-11. 8. Bentzen SM, Constine LS, Deasy JO, Eisbruch A, Jackson A, Marks LB, et al. Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S3-9. 9. Jackson A, Marks LB, Bentzen SM, Eisbruch A, Yorke ED, Ten Haken RK, et al. The lessons of QUANTEC: recommendations for reporting and gathering data on dose- volume dependencies of treatment outcome. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S155-60. 10. Auperin A, Le Pechoux C, Rolland E, Curran WJ, Furuse K, Fournel P, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010;28(13):2181-90. 11. O’Rourke N, Roque IFM, Farre Bernado N, Macbeth F. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev. 2010(6):CD002140. 12. Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv1-iv21. 13. Choy H, LaPorte K, Knill-Selby E, Mohr P, Shyr Y. Esophagitis in combined modality therapy for locally advanced non-small cell lung cancer. Semin Radiat Oncol. 1999;9(2 Suppl 1):90- 6. 14. Wijsman R, Dankers F, Troost EG, Hoffmann AL, van der Heijden EH, de Geus-Oei LF, et al. Multivariable normal-tissue complication modeling of acute esophageal toxicity in advanced stage non-small cell lung cancer patients treated with intensity-modulated (chemo-)radiotherapy. Radiother Oncol. 2015;117(1):49-54. 15. Gomez DR, Tucker SL, Martel MK, Mohan R, Balter PA, Lopez Guerra JL, et al. Predictors of high-grade esophagitis after definitive three-dimensional conformal therapy, intensity- modulated radiation therapy, or proton beam therapy for non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2012;84(4):1010-6.